Quick Answer
SELLAS Life Sciences Group, Inc. reported Total Revenue of $0.00 for fiscal year 2023.
SELLAS Life Sciences Group, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $0.00 -100.0% |
$1.00M -86.8% |
$7.60M +300.0% |
$1.90M |
| Revenue (ASC 606) | — | — | $0.00 -100.0% |
$1.00M -86.8% |
$7.60M +300.0% |
$1.90M |
| Net Income | -$26.86M +13.0% |
-$30.88M +17.3% |
-$37.34M +9.6% |
-$41.30M -99.5% |
-$20.70M -23.5% |
-$16.76M +13.1% |
| Diluted EPS | -$0.25 +50.0% |
-$0.50 +62.7% |
-$1.34 +37.1% |
-$2.13 -59.0% |
-$1.34 +36.5% |
-$2.11 |
| Total Assets | $78.34M +303.2% |
$19.43M +212.5% |
$6.22M -70.3% |
$20.94M -20.3% |
$26.27M -42.9% |
$46.05M +177.3% |
| Cash and Equivalents | $71.79M +417.0% |
$13.89M +448.9% |
$2.53M -85.2% |
$17.12M -19.8% |
$21.36M -39.5% |
$35.30M +385.1% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $70.87M +648.8% |
$9.46M +218.7% |
-$7.98M -264.4% |
$4.85M -76.2% |
$20.35M -27.2% |
$27.96M +358.9% |
| R&D Expense | — | — | — | — | $15.67M +68.9% |
$9.28M +27.4% |
| Operating Income | -$28.27M +10.3% |
-$31.51M +16.8% |
-$37.87M +9.7% |
-$41.95M -65.8% |
-$25.29M -48.9% |
-$16.98M +15.3% |
| Shares Outstanding | 153.10M +107.0% |
73.98M +130.2% |
32.13M +53.0% |
21.01M +32.1% |
15.90M +11.5% |
14.25M +180.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2023 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2023 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$6.79M | +4.5% | -2.9% |
| Diluted EPS | September 30, 2025 | -$0.06 | +40.0% | +14.3% |
| Total Assets | September 30, 2025 | $51.55M | +94.5% | +59.6% |
| Cash and Equivalents | September 30, 2025 | $44.32M | +110.7% | +75.2% |
| Long-Term Debt | September 30, 2018 | $0.00 | — | — |
| Stockholders Equity | September 30, 2025 | $45.63M | +187.1% | +74.5% |
| R&D Expense | September 30, 2021 | $4.54M | +91.8% | +31.4% |
| Operating Income | September 30, 2025 | -$7.08M | +3.4% | -3.1% |
| Gross Profit | September 30, 2013 | $869.0K | — | — |
| Shares Outstanding | September 30, 2025 | 125.08M | +94.3% | +24.6% |
- SELLAS Life Sciences Group, Inc. reported Total Revenue of $0.00 for fiscal year 2023.
- SELLAS Life Sciences Group, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2023.
- SELLAS Life Sciences Group, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Net Income of -$26.86 million for fiscal year 2025.
- SELLAS Life Sciences Group, Inc. showed an increase of +13.0% in Net Income compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Diluted EPS of $0.25 per share (loss) for fiscal year 2025.
- SELLAS Life Sciences Group, Inc. showed an increase of +50.0% in Diluted EPS compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Total Assets of $78.34 million for fiscal year 2025.
- SELLAS Life Sciences Group, Inc. showed an increase of +303.2% in Total Assets compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Cash and Equivalents of $71.79 million for fiscal year 2025.
- SELLAS Life Sciences Group, Inc. showed an increase of +417.0% in Cash and Equivalents compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Long-Term Debt of $0.00 for fiscal year 2018.
- SELLAS Life Sciences Group, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Stockholders Equity of $70.87 million for fiscal year 2025.
- SELLAS Life Sciences Group, Inc. showed an increase of +648.8% in Stockholders Equity compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported R&D Expense of $15.67 million for fiscal year 2021.
- SELLAS Life Sciences Group, Inc. showed an increase of +68.9% in R&D Expense compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Operating Income of -$28.27 million for fiscal year 2025.
- SELLAS Life Sciences Group, Inc. showed an increase of +10.3% in Operating Income compared to the prior fiscal year.
- SELLAS Life Sciences Group, Inc. reported Shares Outstanding of 153.10 million shares for fiscal year 2025.
- SELLAS Life Sciences Group, Inc. showed an increase of +107.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: